GalNAc-Conjugated Oligonucleotides for HBV Seroconversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis B virus (HBV) infection, particularly in NUC-naïve patients, are ineffective in achieving long-term seroconversion and are associated with adverse effects and the risk of negative flares, which can lead to liver disease and hepatocellular carcinoma.
Innovation Solution
Development of oligonucleotides with specific sequences and chemical modifications, such as 2′-fluoro and 2′-O-methyl modifications, and phosphorothioate linkages, conjugated with GalNAc moieties, that selectively inhibit HBV surface antigen expression, inducing a positive immune response and reducing viral load.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current NUC therapies (entecavir, tenofovir) are used to suppress viral load, then plasma viremia is reduced, but HBeAg seroconversion rates remain very low (27-36% after interferon, even lower with NUCs) and lifelong therapy is required
Solution Approach 1:
The invention uses combination therapy with multiple oligonucleotides targeting different HBV genes (S, C, P, and X genes) rather than a single agent. This segmented approach attacks the virus through multiple mechanisms simultaneously, achieving both viral load reduction and higher seroconversion rates without requiring lifelong treatment
Solution Approach 2:
The patent employs composite oligonucleotide structures with specific chemical modifications (2'-fluoro, 2'-O-methyl, phosphorothioate linkages, GalNAc conjugation) combined with multiple targeting sequences. This composite design enhances both the potency for viral suppression and the ability to induce seroconversion
2Reliability
If interferon alpha therapy is administered for 48 weeks, then HBeAg seroconversion occurs in 27-36% of patients, but serious and unpleasant side effects occur
Solution Approach 1:
The oligonucleotide combination acts as an intermediary that achieves seroconversion through a different mechanism than interferon. By targeting specific viral genes and inducing a controlled immune response, the patent achieves comparable or superior seroconversion rates without the severe side effects associated with interferon therapy
Solution Approach 2:
The invention changes the therapeutic parameters by using RNA interference mechanisms instead of interferon's immune modulation. This parameter change allows achieving seroconversion through gene silencing and controlled immune activation, avoiding the harmful side effects while maintaining efficacy
3Quantity of substance
If NUC therapies are used to reduce viral load, then plasma viremia decreases, but the emergence of resistance limits therapeutic efficacy
Solution Approach 1:
The combination of multiple oligonucleotides targeting different viral genes creates multiple barriers to resistance development. The virus would need to develop resistance to multiple different targets simultaneously, which is statistically improbable, thereby maintaining long-term therapeutic efficacy
Solution Approach 2:
The oligonucleotide combination provides multi-functionality by targeting multiple essential viral genes (S, C, P, X). This universal approach ensures that suppression of viral replication occurs through multiple pathways, preventing the virus from escaping through single-point mutations
Data Source
AI summary
The present invention provides oligonucleotides for use in the treatment of hepatitis B or hepatitis B virus infection in a human patient.